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A B S T R A C T
The study consisted of morphometric analysis, assessment of the argyrophilic nucleolar organization region
(AgNOR) characteristics, and image cytometry (ICM) in different tumor mass compartments: bone marrow (BM), pe-
ripheral blood (PB) and lymph nodes (LN) from patients with chronic leukemic lymphoproliferative disorders. A total of
71895 cells were analyzed on SFORM PC (VAMSTEC, Zagreb). Correlation between morphometric, AgNOR and ICM
characteristics revealed the cells with low proliferative activity to possess small, homogeneous AgNOR, with the majority
of cells in the peak of DNA histogram. The cells with high proliferative activity had inhomogeneous AgNOR, mostly con-
taining greater DNA content than peak cells, pathologic mitoses (DNA>4N), or the majority of cells were in the S-phase
of the cell cycle. Cells with medium proliferative activity and annular AgNOR were in-between. Analysis of different tu-
mor mass compartments showed that lymphatic cells with the affinity to accumulate in BM regularly exhibited low
proliferative activity (a lower percentage of cells in SFC and highest percentage of cells in the peak of the G0/G1 phase).
The cells in LN exhibited the characteristics of proliferative cells (an increased number of AgNOR, larger and more
proliferative inhomogeneous AgNOR, and lowest percentage of cells in the G0/G1 phase). The migration of cells from BM
to LN and between lymph nodes occurred through PB (there were cells with low and high proliferative activity: a higher
proportion of cells in SFC and at the same time in the G0/G1 phase of the cell cycle). Analysis of cell size and proliferative
activity in different compartments of tumor mass revealed that the cells in BM and PB did not differ substantially ac-
cording to size and proliferative activity, while an inverse pattern was observed between PB and LN. As small cells are in-
active and larger cells more proliferative, the analysis quite unexpectedly showed the PB cells to be largest and most inac-
tive, in contrast to LN where the cells were smallest and most active. The »single« and »multiple programmed stops«
have been hypothesized in the development of typical forms of leukemias and lymphomas and atypical forms of subacute
and subchronic leukemias. Differentiation impairment may occur at any stage, and different »stop« locations result in
different morphology and affinity to accumulation in bone marrow, peripheral blood and lymph nodes.
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Introduction
Historically, disorders were termed leukemias when
their clinical presentation included a typically abnormal
and frequently increased number of white blood cells in
the peripheral blood, contrary to lymphomas in which
cases enlargement of lymphatic organs was present as a
predominant abnormality1. The World Health Organiza-
tion (WHO) classification of hematopoietic neoplasias de-
scribes chronic lymphocytic leukemia (CLL) as leukemic
neoplasm composed of monomorphic small, round to
slightly irregular B lymphocytes in the peripheral blood
(PB), bone marrow (BM), spleen and lymph nodes (LN),
admixed with prolymphocytes and paraimmunoblasts
forming proliferation centers in tissue infiltrates2. In the
WHO classification, CLL is always a disease of neoplastic
B cells, whereas the entity formerly described as T-CLL is
now called T-cell prolymphocytic leukemia. Other chronic
leukemic lymphoproliferative diseases (CLLPD) that can
masquerade as CLL are hairy cell leukemia, or leukemic
manifestations of mantle cell lymphoma, marginal zone
lymphoma, splenic marginal zone lymphoma with circu-
lating villous lymphocytes, or follicular lymphoma. To
achieve an accurate diagnosis and prognosis3-5, it is es-
sential to evaluate the blood count, blood smear, and the
immune phenotype of the circulating lymphoid cells6,7.
Morphologically, CLL can be classified into typical and
atypical forms. Typical CLL (CLL-TYP) is the most com-
mon morphological form of CLL with less than 10% of
prolymphocytes of peripheral blood lymphatic cells. Aty-
pical CLL (CLL-ATYP) comprises two subtypes: chronic
lymphocytic leukemia/prolymphocytic leukemia (CLL/PL)
with increased prolymphocytes in peripheral blood
(10–55%) and atypical CLL with lymphoplasmacytoid
differentiation and/or presence of cleaved cells (CLL/
LP)8.
Morphometric analysis allows for the objective quan-
tification of a set of parameters, or features representing
the cell. The analysis showed that each class of cells is as-
sociated with a set of unique parameters, which provide
significant information in the analysis of lymphopro-
liferative disorders and may serve as an additional tool
for the morphological evaluation of diseases9. Chronic
CLL-TYP and ATYP as well as other CLLPD are low
grade neoplasms with a diploid DNA index and low but
variable proliferative activity10. Apparently, most cells
are in G0 phase, but recent studies comparing expression
of cell cycle regulatory proteins in these diseases with
that of normal resting and stimulated lymphocytes sug-
gest that the neoplastic cells are arrested in early G1
phase or at the G0/G1 transition10–12. The argyrophilic
nucleolar organization regions (AgNOR) are widely stud-
ied as a proliferation marker to analyze the proportion of
cells in proliferative cell cycle, in tumor pathology in gen-
eral, as well as in lymphoproliferative disorders10,13,14.
Conventional kinetic studies are irrelevant in B-CLL
since the great majority of circulating cells are in G0 or
G1 phases, which are indistinguishable from one another
by flow cytometry determination of DNA content12. The
new parameters of modified analysis of diploid histogram
seem to be appropriate for kinetic analysis by the method
of image DNA cytometry, and with newly characterized
types of AgNOR points, homogeneous, inhomogeneous
and annular, play a role in calculating the prolifera-
tive-kinetic index of lymphoproliferative disorders15.
The aim of the study was to identify the specific
morphometric, proliferative and/or kinetic parameters in
different tumor mass compartments, i.e. bone marrow,
peripheral blood and lymph node. Then, the proliferative
and kinetic parameters were used in an attempt to assess
the origin and distribution of malignant lymphatic cells
in various clinical and morphological entities.
Material and Methods
The study was performed on cytologic smears of bone
marrow, peripheral blood and lymph node FNA samples
collected from patients with leukemic forms of CLLPD
classified according to WHO classification. The analysis
was carried out in the entire CLLPD population, and in
the B-CLL-TYP and B-CLL-ATYP subgroups separately.
The following parameters obtained by computer analysis
were assessed: image morphometric characteristics of
the cell and nucleus (IM); image characteristics of AgNOR
(IAgNOR); and image DNA cytometry (ICM). A total of
657 smears (71895 cells) were analyzed by the three
methods in different tumor mass compartments (bone
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Fig. 1. Image analysis of patients with B chronic lymphocytic
leukemia/prolymphocytic leukemia: I) bone marrow, II) lymph
node, III) peripheral blood, a) morphometry, b) AgNOR, c) image
DNA cytometry).
marrow, lymph node and peripheral blood) (Figure 1).
Averages of 100 cells were analyzed for IM and IAgNOR,
and 120–250 cells for ICM. Fresh and archival smears
stained according to May-Grünwald-Giemsa (MGG) were
used for morphometric analysis, according to Feulgen
(Merck, Germany, Kit N.1.07907/3) for ICM, and silver
impregnation for IAgNOR16. For morphometric analysis,
the cytoplasmatic and nuclear margins were interac-
tively marked (the cytoplasm first, then the nucleus),
with manual correction. The following parameters of nu-
clei as well as of cytoplasms of cells were analyzed: area,
outline, convexity, minimal and maximal radius, length
(L) and breadth (B), regularity factors (FF-4p area/r2 and
elongation FF-L/B), and nucleus to cytoplasm ratio (N/C)17.
The number, area (minimal, maximal and mean), and
AgNOR to nucleus ratio were analyzed for each AgNOR
type (homogeneous, inhomogeneous and annular); then
total number of all AgNORs; total area (minimal, maxi-
mal and mean); and ratio of total area of all AgNOR and
nuclear area. A modified method of diploid type DNA his-
togram analysis according to Kardum-Skelin15 was em-
ployed, with determination of DNA index (DI), synthetic
(S) phase according to Cornelisse et al.18, and cell per-
centage of DNA greater than 4N. Granulocytes (n20)
were used as internal control. The analysis was done on a
PC using the SFORM supporting software (Vamstec,
Zagreb, Croatia). Statistical processing of the results was
performed by the Statistica 7.1 program (StatSoft, Inc.,
Tulsa, USA).
Results
Correlation of the IM, IAgNOR and ICM image
parameters analyzed
(a) In total cell population of leukemic forms of chro-
nic lymphoproliferative diseases (CLLPD)
Spearman rank correlation was used among mor-
phometric characteristics, AgNOR characteristics and
tumor cell DNA histogram in various tumor mass com-
partments, i.e. bone marrow, peripheral blood and lymph
nodes (Figure 1), in CLLPD patients and in separately in
the subgroups with B-CLL-TYP and B-CLL-ATYP. The
highest rate of statistically significant correlations was
recorded in peripheral blood lymphatic cells (Table 1).
Morphometric characteristics of the cell and nucleus
showed negative correlation with homogeneous AgNOR
characteristics (larger cells and nuclei had a lower num-
ber and area of homogeneous AgNOR), whereas the
characteristics of inhomogeneous and annular AgNOR
as well as total number and area of all AgNOR yielded
positive correlation with the cell and nucleus size, cir-
cumference and other morphometric characteristics ana-
lyzed. When compared with DNA histogram characteris-
tics, the cell and nucleus morphometric characteristics
also showed certain regular patterns. Larger cells and
nuclei were associated with a higher percentage of cells
containing >4N DNA. Inhomogeneous AgNOR, total
area of all AgNOR, and ratio of total AgNOR area and
nucleus were greater when the percentage of cells in the
peak was lower. The number and area of inhomogeneous
AgNOR correlated positively with the percentage of cell
containing a greater content of DNA than peak cells,
higher percentage of cells containing >4N DNA, and
higher percentage of cells in the S-phase of the cell cycle.
At the same time, greater area of all AgNOR correlated
positively with the percentage of cells containing >4N
DNA. Unlike inhomogeneous AgNOR, annular AgNOR
and ratio of annular AgNOR and nucleus showed an in-
verse relation with the percentage of cells containing
>4N DNA or percentage of cells in the S-phase of the cell
cycle.
Like in the peripheral blood, in the bone marrow ho-
mogeneous AgNOR showed negative correlation with
cellular and nuclear morphometric characteristics, whe-
reas the characteristics of inhomogeneous and annular
AgNOR as well as the number and area of all AgNOR
correlated positively with the size, circumference and
other cell and nucleus morphometric characteristics ana-
lyzed. DI and percentage of cells in the peak of DNA his-
togram showed an inverse relation with the cell and nu-
cleus size. Larger cells and nuclei were associated with a
higher percentage of cells containing higher DNA con-
tent than peak cells. As well as in a higher percentage of
cells in the S-phase of the cell cycle. Comparison of
AgNOR characteristics and DNA histogram characteris-
tics revealed the percentage of cells containing lower
DNA content than the diploid peak of the histogram to
correlate positively with the number and area of homoge-
neous AgNOR. The higher the percentage of cells with
DNA content greater than peak cells, the the larger was
the area of all AgNOR. The number and area of inho-
mogeneous AgNOR correlated positively with the per-
centage of cells that also contained more DNA than those
in the peak of DNA histogram, while yielding an inverse
relationship with the percentage of cell in the peak.
Analysis of the morphometric characteristics of the
lymph node lymphatic cells revealed only N/C ratio to
show negative correlation with homogeneous AgNOR.
Maximal cell radius yielded positive correlation with the
area of inhomogeneous AgNOR, and the number and to-
tal area of all AgNOR. The lymph node lymphatic cells
showed a considerably lower rate of correlations between
DNA and AgNOR characteristics; only the total number
and area of AgNOR were greater with a higher percent-
age of cells containing DNA >4N.
(b) In the subgroup of patients with typical and atypi-
cal CLL (B-CLL-TYP and B-CLL-ATYP)
In this subgroup, the percentage of cells with lower
DNA content than peak cells correlated positively with
the number of homogeneous AgNOR in bone marrow
lymphatic cells. The characteristics of inhomogeneous
AgNOR (number and area) showed an inverse correla-
tion with the percentage of cells in the peak of DNA his-
togram, while yielding positive correlation with the per-
centage of cells with DNA content exceeding that in the
peak cells or DNA content >4N.
A similar pattern was recorded for peripheral blood
lymphatic cells: the lower the number of cells in the dip-
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loid peak of DNA histogram, the higher was the number
and area of inhomogeneous AgNOR. At the same time,
the greater the number of cells with DNA content ex-
ceeding that in the peak cells or >4N, or the more cells in
the S-phase of the cell cycle, the greater was the number
and area of inhomogeneous AgNOR. The correlation of
total area of all AgNOR and ratio of total area of all
AgNOR/nucleus followed a similar pattern: these param-
eters were lower with the higher percentage of cells in
PEAK and higher with the greater percentage of cells
containing >4N DNA. Homogeneous AgNOR in the lym-
ph node lymphatic cells had greater area when the per-
centage of cells containing less DNA than peak cells was
higher, with greater ratio of homogeneous AgNOR/nu-
cleus, and when fewer cells were in the S-phase of the cell
cycle. Total number and area of all AgNOR, and the ratio
of total area of all AgNOR/nucleus were greater when the
percentage of cells with DNA content exceeding that in
the peak cells was higher or when there were more cells
with DNA content >4N.
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TABLE 1
SPEARMAN RANK CORRELATION BETWEEN MORPHOMETRIC CHARACTERISTICS, ARGYROPHILIC NUCLEOLAR ORGANIZATION RE-
GION CHARACTERISTICS AND LYMPHATIC CELL DNA HISTOGRAM IN PERIPHERAL BLOOD OF LEUKEMIC LYMPHOPROLIFERATIVE
DISEASE PATIENTS
Spearman Rank Order Correlations
PBAGAHOM/N PBAGAINH PBAGNAN PBAGATOT PBDNA%S>4N
PBMAC –0.260286* 0.411878* 0.002588 0.520050* 0.268947*
PBMOC –0.231187 0.354180* 0.012462 0.460307* 0.275398*
PBMMIRC –0.368542* 0.448534* 0.020353 0.544974* 0.112562
PBMMARC –0.182966 0.329715* 0.003340 0.442939* 0.251818
PBMCAC –0.248888* 0.403110* –0.007118 0.501597* 0.275175*
PBMLC –0.182006 0.339860* 0.017222 0.462311* 0.263830
PBMBC –0.286254* 0.430247* –0.048555 0.483728* 0.262273
PBMFFC –0.042981 0.215071 –0.202215 0.145684 –0.197539
PBMFFEC 0.059096 –0.104770 0.171132 0.027325 0.082753
PBMSUMAN –0.279491* 0.393216* 0.040852 0.548648* 0.219784
PBMN/C 0.115332 –0.232022 –0.012692 –0.304874* –0.238025
PBMAN –0.278196* 0.402067* 0.040101 0.561257* 0.213556
PBMON –0.236739 0.335393* 0.054212 0.474752* 0.208439
PBMMIRN –0.303914* 0.431375* –0.013318 0.568312* 0.100327
PBMMARN –0.207181 0.328588* 0.046781 0.456925* 0.222009
PBMCAN –0.269387* 0.386452* 0.045695 0.541008* 0.219784
PBMLN –0.220708 0.342407* 0.052187 0.481641* 0.234021
PBMBN –0.299113* 0.442396* –0.016011 0.557040* 0.187528
PBMFFN –0.092078 0.238409 –0.220167 0.190606 –0.082530
PBMFFIN –0.022398 –0.020436 0.168168 0.042396 0.048050
PBDNADI –0.085971 –0.027394 0.115021 0.181850
PBDNA%CPIK 0.310507 –0.487430* 0.177307 –0.419512*
PBDNA%C<PIK –0.074488 –0.060322 0.086687 0.052160
PBDNA%C>PIK –0.085378 0.330534* –0.184509 0.201435
PBDNA%C>4N 0.053809 0.411988* –0.282203 0.317514*
PBDNA%SFC –0.104367 0.321613* –0.324771* 0.136893
*Correlations significant at p<0.05 (marked in red), PB – peripheral blood, MAC – cell area (mm2), MOC – cell outline, MIRC – cell min-
imum radius; MARC – cell maximum radius, MCAC – cell convex area (mm2), MBC – cell breadth; MLC – cell length, MFFC – cell regu-
larity (4p area/r2), MFFEC – cell elongation (length/breadth), MAN – nuclear area (mm2), MON – nuclear outline, MIRN – nuclear min-
imum radius, MARN – nuclear maximal radius, MCAN – nuclear convex area (mm2), MLN – nuclear length, MBN – nuclear breadth,
MFFN – nuclear regularity (4p area/r2), MFFEN – nuclear elongation (length/breadth), AGAINHOM – area of inhomogeneous
AgNOR (mm2), AGNAN – number of annular AgNOR, AGATOT – total number of AgNOR, AGHOM/N – ratio of homogeneous
AgNOR area and area of nucleus, DNADI – DNA index; DNA%CPIK – percentage of cells in peak of DNA histogram, DNA%C<PIK –
percentage of cells with lower contents of DNA than cells in peak of DNA histogram, DNA%C>PIK – percentage of cells with higher
contents of DNA than cells in peak of DNA histogram, DNA%C>4N – percentage of cells with higher contents DNA than 4N; DNA%
CSFC – percentage of cells in S-phase
Distribution of cells in different compartments
of tumor mass
(a) Bone marrow and peripheral blood
The area (99.79±22.93 mm2) and regularity of nuclei
(0.84±0.02) in peripheral blood lymphatic cells were stati-
stically significantly greater than in bone marrow lympha-
tic cells (area 90.62±16.70 mm2 and regularity 0.82±0.02)
in total CLLPD population (p=0.002273 for area and
p=0.000275 for regularity) as well as in the B-CLL-
-TYP&ATYP subpopulation (p=0.005566 for area and
p=0.000275 for regularity). The nucleus to cytoplasm ra-
tio was lower in peripheral blood (CLLPD 0.70±0.06 and
B-CLL-TYP&ATYP 0.71±0.06) than in bone marrow
(CLLPD 0.74±0.04 and B-CLL-TYP&ATYP 0.74±0.03)
and in both groups (larger lymphatic cell nuclei and
lesser cytoplasm in bone marrow) (Table 2, Figure 2).
(b) Bone marrow and lymph node
In comparison with lymph node, bone marrow sho-
wed a statistically significantly lower number (0.31±0.19
for bone marrow and 0.56±0.33 for lymph node) and
smaller total area of homogeneous AgNOR (0.26±0.16 for
bone marrow and 0.44±0.26 for lymph node), and lower
minimal, maximal and mean values of these parameters.
Lymph node was associated with a lower number of an-
nular AgNOR (lymph node 0.33±0.22 and bone marrow
0.46±0.24), greater number of total AgNOR (lymph node
1.55±0.32 and bone marrow 1.42±0.23), and lower cell
percentage in the peak of DNA histogram (lymph node
32.80±10.90 and bone marrow 36.24±8.98) in total CLLPD
population and B-CLL-TYP&ATYP subgroup (Table 3).
(c) Peripheral blood and lymph node
The difference of morphometric parameters of lym-
phatic cell area (CLLPD, p=0.000143 and B-CLL-TYP&
ATYP, p=0.000627) and convexity of the cell surface
(CLLPD, p=0.000005 and B-CLL-TYP&ATYP, p=0.000002)
and nucleus were statistically significantly i.e. those pa-
rameters were lower in lymph node than in peripheral
blood. The AgNOR characteristics, i.e. the number (CLLPD,
p=0.000576 and B-CLL-TYP&ATYP, p=0.000243) and
area of homogeneous AgNOR (CLLPD, p=0.000576 and
B-CLL-TYP&ATYP, p=0.000246) and their ratio relative
to the nucleus (CLLPD, p=0.002918 and B-CLL-TYP&
ATYP, p=0.003708) were lower in peripheral blood. The
number of annular AgNOR (CLLPD p=0.002943 and
B-CLL-TYP&ATYP, p=0.003685), their total area (CLLPD,
p=0.023458 and B-CLL-TYP&ATYP, p=0.033089) (Fig-
ure 3), and their minimal (CLLPD, p=0.026769 and
B-CLL-TYP&ATYP, p=0.031885) and maximal area
(CLLPD, p=0.023417 and B-CLL-TYP&ATYP, p=0.030083)
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Fig. 2. a) Nucleo/cytoplasm ratio of bone marrow (BMMN/C) and
peripheral blood (PBMN/C) lymphatic cells of patients with
chronic leukemic lymphoproliferative disorders and b) B chronic
lymphocytic leukemia; statistically significant, p<0.01.
TABLE 2
STATISTICALLY SIGNIFICANT DIFFERENCES IN IMAGE PARAMETERS OF BONE MARROW AND PERIPHERAL BLOOD LYMPHATIC
CELLS
VARIABLE
CLLPD B-CLL(T&A)
p
BM
X±SD
PB
X±SD
P
BM
X±SD
PB
X±SD
BMMAC # PBMAC (mm2) 0.002273 90.62±16.70 99.79±22.93 0.005566 89.62±12.53 97.38±20.40
BMMFFJ # PBMFFN 0.000275 0.82±0.02 0.84±0.02 0.000275 0.83±0.03 0.84±0.03
BMMN/C # PBMN/C 0.000010 0.74±0.04 0.70±0.06 0.000044 0.74±0.03 0.71±0.06
X – mean, SD – standard deviation; p – probability of a statistically significant difference, NS – statistically nonsignificant; CLLPD –
chronic leukemic lymphoproliferative disorders, B-CLL(T&A) – B chronic lymphocytic leukemia (typical and atypical), BM – bone
marrow, PB – peripheral blood; LN – lymph node, MAC – cell area, MFFN – nuclear regularity (4p area/r2), MN/C – nucleo-cytoplasmic
ratio
were greater in peripheral blood lymphatic cells than in
lymph node lymphatic cells (Table 4). Cell percentage in
the peak of DNA histogram (CLLPD, p=0.009674 and
B-CLL-TYP&ATYP, p=0.011876) (Figure 4) was lower in
lymph node as compared with peripheral blood in both
study groups.
Discussion and Conclusion
Morphometric characteristics of the cells and/or nu-
clei, DNA content and AgNOR characteristics have been
analyzed in various benign19,20, premalignant and malig-
nant lesions of different organs21, including leukemias
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TABLE 3
STATISTICALLY SIGNIFICANT DIFFERENCES IN IMAGE PARAMETERS OF BONE MARROW AND LYMPH NODE LYMPHATIC CELLS
VARIABLE
CLLPD B-CLL(T&A)
P
BM
X±SD
LN
X±SD
P
BM
X±SD
LN
X±SD
BMAGNHOM # LNAGNHOM 0.000006 0.31±0.19 0.56±0.33 0.000014 0.31±0.17 0.56±0.34
BMAGAHOM # LNAGAHOM 0.000046 0.26±0.16 0.44±0.26 0.000042 0.26±0.14 0.45±0.26
BMAGNAN # LNAGNAN 0.006717 0.46±0.24 0.33±0.22 0.003040 0.48±0.22 0.33±0.22
BMAGNTOT # LNAGNTOR 0.015294 1.42±0.23 1.55±0.32 0.012914 1.43±0.16 1.54±0.35
BMDNA%CPEAK# KSDNA%CPEAK 0.010407 36.24±8.98 31.80±10.90 0.002434 37.56±7.76 32.08±11.36
X – mean, SD – standard deviation, p – probability of a statistically significant difference, NS – statistically nonsignificant, CLLPD –
chronic leukemic lymphoproliferative disorders, B-CLL(T&A) – B chronic lymphocytic leukemia (typical and atypical), BM – bone
marrow; PB – peripheral blood, LN – lymph node, AGNHOM – number of homogeneous AgNOR, AGAHOM – area of homogeneous
AgNOR (mm2), AGNAN – number of annular AgNOR, AGNTOT – total number of AgNOR, KSDNA%CPEAK – percentage of cells in
peak of DNA histogram
p=0,023458 (p<0,05)
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b)
Fig. 3. a) Area of annular AgNOR (mm2) of peripheral blood
(PBAGAAN) and lymph node (LNAGAAN) lymphatic cells of pa-
tients with chronic leukemic lymphoproliferative disorders and
b) B chronic lymphocytic leukemia; statistically significant,
p<0.05.
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Fig. 4. a) Percentage of cells in peak of DNA histogram of periph-
eral blood (PBDNA%CPEAK) and lymph node (LNDNA%
CPEAK) lymphatic cells of patients with chronic leukemic lym-
phoproliferative disorders and b) B chronic lymphocytic leuke-
mia; statistically significant, p<0.05.
and lymphomas22–25. In contrast to most studies that
used some of the quantitative morphometric methods26,
AgNOR analysis25 and ICM27, Böcking et al.28 employed
multimodal cell analysis that included nucleus morpho-
metry, chromatin structure, nucleolar characteristics,
AgNOR and DNA-ICM, in order to upgrade diagnostic
accuracy of malignant tumors through analysis of sam-
ples with a small number of atypical cells and thus im-
proving the early diagnosis of those diseases. The rela-
tion of AgNOR number and ploidy remains a controver-
sial issue29,30. Some studies failed to demonstrate correla-
tion between AgNOR parameters and DNA parameters31.
However, analysis of the relation of AgNOR aggregates
and cell proliferation in general, not only in the diagnosis
of malignancy, has shown that the number of AgNOR ag-
gregates per nucleus does not correlate well with higher
proliferative activity, while the size of these aggregates
was consistently related to the cell proliferation32. Our
results demonstrated the correlation among morpho-
metric characteristics, proliferative characteristics of dif-
ferent AgNOR types, and newly described features of the
diploid type of histogram. Based on these, the following
conclusions were drawn: cells with low proliferative ac-
tivity are those that have small homogeneous AgNOR
and most cells in the peak of DNA histogram; highly
proliferative cells have inhomogeneous AgNOR and most
of them have DNA content higher than peak cells, or
there are pathologic mitoses (DNA >4N), or a greater
number of cells are in the S-phase of the cell cycle. Cells
with medium sized annular AgNOR are somewhere in-
-between.
Previous studies of lymphatic cells were generally
performed in a single tumor mass compartment, mostly
on peripheral blood smear33,34 or lymph node35. Jak{i} et
al.4 were the first to analyze the relationship of adhesion
molecules as major factors in tumor mass distribution
among particular tumor mass compartments. In the
present study, morphometric and kinetic characteristics
of tumor cells were analyzed for the first time, and com-
pared among different tumor mass compartments: bone
marrow, peripheral blood and lymph nodes in the same
patient. In these compartments, neoplastic cells are found
in different microenvironments. Our results indicated
that lymphatic cells with affinity for accumulation in
bone marrow as a rule had low proliferative activity (the
highest percentage of cells in the peak of G0/G1 phase).
The cells performing affinity to accumulate in lymph
nodes, migrated to lymph nodes (higher number of total
AgNOR, higher area of proliferative inhomogeneous
AgNOR and lowest percentage of cells in the G0/G1
phase). Cell migration from bone marrow to lymph nodes
and between lymph nodes takes place through the periph-
eral blood (where a mixture of cells with lower and
higher proliferative activity was found; a higher percent-
age of cells in synthetic phase of cell (SFC) and concur-
rently in the G0/G1 phase of the cell cycle; larger cells
with smaller nuclei with annular AgNOR of the interme-
diary grade of proliferation). Peripheral blood appeared
to have just a transport role.
Analysis of the cell size and proliferative activity in
different tumor mass compartments indicated a regular
pattern in both total CLLPD population and B- CLL-
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TABLE 4
STATISTICALLY SIGNIFICANT DIFFERENCES IN IMAGE PARAMETERS OF PERIPHERAL BLOOD AND LYMPH NODE LYMPHATIC
CELLS OBTAINED BY IMAGE COMPUTER ANALYSIS
VARIABLE
CLLPD B-CLL(T&A)
P
PB
X±SD
LN
X±SD
P
PB
X±SD
LN
X±SD
PBMAC # LNMAC (mm2) 0.000143 99.79±22.93 86.10±15.35 0.000627 97.38±20.40 85.73±11.90
PBMCAC # LNMCAC (mm2) 0.000005 102.56±24.37 88.22±15.92 0.000002 100.06±22.01 87.75±12.27
PBAGBNOM # LNAGNHOM 0.000576 0.31±0.33 0.56±0.33 0.000243 0.29±0.20 0.56±0.34
PBAGAHOM # LNAGAHOM (mm2) 0.000576 0.28±0.22 0.44±0.26 0.000246 0.27±0.20 0.45±0.26
PBAGHOM/N #LNAGHOM/N 0.002918 0.004±0.003 0.01±0.02 0.003708 0.004±0.003 0.01±0.03
PBAGNAN # LNAGNAN 0.002943 0.48±0.26 0.33±0.22 0.003685 0.49±0.27 0.30±0.22
PBAGAAN # LNAGAAN (mm2) 0.023458 1.90±0.26 1.44±1.13 0.033089 1.90±1.07 1.42±1.08
PBAGMAN # LNAGMAN (mm2) 0.023458 1.93±1.11 1.36±1.08 0.045500 1.90±0.97 1.33±1.01
PBAGMIAN # LNAGMIAN (mm2) 0.026769 1.79±1.01 1.35±1.07 0.031885 1.75±0.96 1.32±1.00
PBAGMAAN # LNAGMAAN (mm2) 0.023417 1.84±1.04 1.38±1.08 0.030083 1.80±0.99 1.35±1.02
PBDNA%CPEAK # LNDNA%CPEAK 0.009674 36.75±10.47 31.80±10.90 0.011876 37.50±10.75 32.08±11.36
X – mean, SD – standard deviation, p – probability of a statistically significant, NS – statistically nonsignificant, CLLPD – chronic leu-
kemic lymphoproliferative disorders, B-CLL(T&A) – B chronic lymphocytic leukemia (typical and atypical), BM – bone marrow, PB –
peripheral blood, LN – lymph node, MAC – cell area (mm2), MCAC – cell convex area (mm2), AGNHOM – number of homogeneous
AgNOR, AGAHOM – area of homogeneous AgNOR (mm2), AGHOM/N – ratio of homogeneous AgNOR area and area of nucleus,
AGNAN – number of annular AgNOR; AGAAN – area of annular AgNOR (mm2), AGSMAN – average area of annular AgNOR (mm2),
AGMIAN – minimum area of annular AgNOR (mm2), AGMAAN – maximum area of annular AgNOR (mm2), KSDNA%CPEAK – per-
centage of cells in peak of DNA histogram
-TYP&ATYP subgroup. Whereas bone marrow and pe-
ripheral blood cells did not differ substantially according
to size and proliferative activity, comparison of periph-
eral blood and lymph node cells produced different re-
sults. To the contrary of what was expected, as small cells
are more indolent and larger ones more proliferative, the
analysis showed the cells in peripheral blood to be the
largest and most indolent, in contrast to lymph node cells
that were smallest and most active. The analysis in-
cluded routine slides, posing the question of various
preparation techniques employed for lymph node, bone
marrow and peripheral blood FNA smears. The results
obtained can be confirmed or challenged by measuring
cells in native sample. Although the great majority of sta-
tistically significant parameters compared were recorded
in peripheral blood, a peripheral blood sample alone is
neither representative nor adequate to study prolifera-
tive activity or disease stability, thus posing the question
of careful evaluation of these parameters in all tumor
mass compartments36.
The question is whether our results could be consid-
ered in explaining the hypothesis of »single« and »multi-
ple stops« to elucidate the pathogenesis of typical leuke-
mias and lymphomas as well as various leukemic forms
of chronic lymphoproliferative diseases (Figure 5). Lym-
phoproliferative disorders develop because of deranged
differentiation of lymphatic cells and the consequent ac-
cumulation of long-living functionally inactive neoplastic
B-lymphocytes arrested in the G0 phase of the cell cy-
cle37,38. Dysregulation of differentiation occurs early in
the bone marrow, and these »damaged« cells continue to
proliferate and differentiate in the primary (bone mar-
row) and secondary lymphatic organs (lymph nodes, sp-
leen, etc.), imitating the normal course of reactive cell de-
velopment to the moment of »programmed stop« at which
point accumulation of lymphatic cells of a more mature
or immature morphological appearance occurs. The fun-
ctional inactivity of pathological cells and immunodefi-
ciency result in a vicious circle, i.e. stimulus to the bone
marrow to direct stem cells to immunocompetent cells,
which, due to unregulated differentiation, cannot differ-
entiate into functionally active B- and/or T-lymphocytes
and satisfy the peripheral demand. The accumulation of
pathological cells in the lymph nodes, bone marrow and/
or peripheral blood leads to the development of lympho-
proliferative diseases (leukemia and lymphoma). Which
mechanisms are responsible for derangement of differen-
tiation and the consequent accumulation of pathological
cells? Demonstration of the BCL2, BCL6 and IGV genes
and their products has shown that malignomas with or
without mutated genes belong to different prognostic
groups, heterogeneous in morphological and clinical fea-
tures. As an example serve separate groups of diffuse
large B-cell lymphoma (DLBCL) classified according to
biological characteristics of the tumor by the correspond-
ing degree of B-cell differentiation. Two major DLBCL
subtypes have been defined, one with the presence of ger-
minal-center B-cell gene expression (B-cell-like profile,
GCB) and the other with low expression of B-cell germi-
nal-center genes and expression of normally activated
B-cell genes (activated B-cell-like profile, ABC). There is
a significant difference in survival between these two
DLBCL groups. Will the discovery of different gene mu-
tations (one or more mutations) for each derangement in
differentiation follow in the future? Are somatic gene
mutations alone accountable for different morphological
and clinical features? According to the currently adopted
WHO classification, certain instances of leukemic forms
and localized diseases are considered to be different man-
ifestations of the same disease (B-lymphoblastic leuke-
mia/B-lymphoblastic lymphoma on the one hand and
B-chronic lymphocytic leukemia/B-lymphocytic lympho-
ma of small cells on the other hand). Does the binding of
adhesion molecules as major factors in the distribution of
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Fig. 5. Hypothesis of »single« and »multiple« programmed stops
in the development of chronic lymphoproliferative diseases: PB –
peripheral blood; BM – bone marrow; LN/SP – lymph node/spleen;
ALL (typical acute lymphatic leukemia) – »single programmed
stop« at an earlier stage of development; NHL (typical Non-Hod-
gkin lymphoma) – »single programmed stop« also at an earlier
stage of development; SAL (subacute leukemia) – »multiple pro-
grammed stops» at an earlier stage of development; CLL (typical
chronic lymphocytic leukemia) – »single programmed stop« at a
high stage of differentiation; SCL (subchronic leukemia) – »mul-
tiple programmed stops« at a higher stage of differentiation;
CLL/PLL, CLL/IMC (variant of chronic lymphocytic leukemia) –
»single or multiple programmed stops« at the middle of the dif-
ferentiation process, ALL – acute lymphoblastic leukemia, NHL
(HG) – non-Hodgkin lymphoma (high grade), NHL (LG) – non-
-Hodgkin lymphoma (low grade)
tumor mass among particular tumor compartments play
a role in clinical manifestation of the disease4?
Are, therefore, leukemias and lymphomas a single
disease entity with different clinical manifestations as
the result of different tumor mass distribution in various
compartments (lymphoid organs, bone marrow and pe-
ripheral blood)? Is it more appropriate to consider them
separate diseases developing due to dysregulated differ-
entiation, which can occur at any particular stage (at sin-
gle or multiple points), where different points of »stop«
result in heterogeneous morphology and affinity towards
accumulation in the bone marrow, peripheral blood and
lymph node (also taking into account the issue of micro-
environment). These cases should not be included in the
same therapeutic trials as B-CLL.
The hypothesis is that a »programmed stop« occurs at
various stages of differentiation (but at a single point),
smaller or larger lymphatic cells infiltrate the lymph
node, and the clinical presentation of a malignant lym-
phoma develops (small cell or large cell type of lym-
phoma, depending on the point of »stop« and stage of dif-
ferentiation and maturation).
In case when the »stop« occurs at a later stage of dif-
ferentiation and maturation, also at a single point, the
small indolent lymphocytes accumulate in the bone mar-
row and peripheral blood and lead to clinical presenta-
tion of typical chronic lymphocytic leukemia.
Differentiation arrested between the two extremes (at
one and/or more points) leads to the accumulation of me-
dium-sized lymphatic cells which have a high migration
potential resulting in clinical presentation of B-prolym-
phocytic leukemia and variants of chronic lymphocytic
leukemia (chronic lymphocytic/prolymphocytic leukemia
or chronic lymphocytic leukemia with lymphoplasmacy-
toid differentiation).
However, since in the oncogenesis of lymphatic cells
the »programmed stop« never occurs at a single point but
rather multiple damages are possible, it is obvious that
there are transitions between the three typical forms of
the disease, as well as morphological and proliferative
variations in different tumor mass compartments, and
those results in clinical heterogeneity.
»Multiple stops« shifted towards a high stage of dif-
ferentiation are the cause of accumulation of well differ-
entiated indolent cells in the bone marrow and proli-
ferative cells with a predilection for the lymph node,
resulting in clinical presentation of subchronic leuke-
mias (SCL).
»Multiple stops« at an earlier stage of differentiation
result in the accumulation of highly proliferative cells
with a predilection for lymph node and more indolent
cells with migration potential, leading to clinical presen-
tation of subacute leukemias (SAL).
Both subtypes (subacute and subchronic leukemias)
can be divided into TYPE A – leukemic form with atypi-
cal lymphatic cell counts of >5´109/L in peripheral blood
with infiltration of the bone marrow and lymph nodes,
and TYPE B – subleukemic form with lymph node en-
largement, bone marrow infiltration >40% but less than
5´109/L of malignant cells in peripheral blood. Additional
genomic studies are warranted to establish their precise
nature39.
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MULTIMODALNA STANI^NA ANALIZA U KRONI^NIM LEUKEMIJSKIM
LIMFOPROLIFERATIVNIM BOLESTIMA I HIPOTEZA »JEDNOSTRUKIH« I »VI[ESTRUKIH«
PROGRAMIRANIH STOPOVA U NASTANKU TIPI^NIH I ATIPI^NIH OBLIKA LEUKEMIJA I
LIMFOMA
S A @ E T A K
Studija je obuhvatila morfometrijsku analizu, analizu osobina regije nukleolarne organizacije (AgNOR) te stati~ku
DNA citometriju u razli~itim odjeljcima tumorske mase: ko{tanoj sr`i (KS), perifernoj krvi (PK) i limfnim ~vorovima
(L^) u bolesnika s kroni~nim leukemijskim limfoproliferativnim bolestima. Ukupno je analizirano 71895 stanica, na
osobnom ra~unalu »SFORM« tvrtke VAMSTEC, Zagreb. Me|usobnom analizom morfometrijskih, proliferacijskih i ki-
neti~kih pokazatelja vidjelo se kako nisko proliferativne stanice imaju male homogene AgNOR-e te ve}inu stanica u
vr{ku DNA histograma. Visoko proliferativne stanice su s inhomogenim AgNOR-ima, od kojih ve}ina sadr`i koli~inu
DNA ve}u od stanica u vr{ku; patolo{ke mitoze (DNA>4N) ili ve}i broj stanica u S-fazi stani~nog ciklusa. Negdje u
sredini su srednje proliferativne stanice s prstenastim AgNOR-ima. Analizom u razli~itim odjeljcima tumorske mase
vidljivo je kako limfati~ne stanice koje imaju afinitet prema akumulaciji u KS, u pravilu imaju malu proliferativnu
aktivnost (najve}i postotak stanica u vr{ku Go/G1 faze). Stanice s afinitetom prema akumulaciji u L^ imaju ve}i broj
ukupnih AgNOR-a, ve}u povr{inu proliferativnijih, inhomogenih AgNOR-a i najmanji postotak stanica u Go/G1 fazi.
Sama migracija stanica iz KS prema L^ kao i izme|u L^ doga|a se u PK gdje su prisutne stanice s ni`om i vi{om
proliferativnom aktivnosti (vi{i postotak stanica u S-fazi i istodobno u Go/G1 fazi stani~nog ciklusa kao i prisustvo ve}ih
stanica, ali manjih jezgara, s prstenastim AgNOR-ima intermedijalnog stupnja proliferativnosti). Izgleda kako PK ima
samo transportnu ulogu. Analiziraju}i veli~inu stanica i njihovu proliferativnu aktivnost u razli~itim odjeljcima tu-
morske mase uo~eno je da se stanice u KS i PK ne razlikuju bitno po veli~ini i proliferativnoj aktivnosti, dok je obrnuta
situacija ako se gleda PK i L^. Nasuprot o~ekivanju, kako su male stanice mirnije, a ve}e proliferativnije, analiza je
pokazala da su u PK stanice najve}e i najmirnije, za razliku od L^ gdje su najmanje i najaktivnije. Postavljena je hipo-
teza jednostrukih i vi{estrukih »programiranih stopova» u nastanku tipi~nih oblika leukemija i limfoma te subakutnih
i subkroni~nih leukemija. Poreme}aj diferencijacije mo`e nastati na bilo kojem stupnju, a razli~ito mjesto »stopa« rezul-
tira razli~itom morfologijom te razli~itim afinitetom prema akumulaciji u KS, PK I L^.
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